Tech Company Financing Transactions
Tome Biosciences Funding Round
Tome Biosciences closed a $213 million Series A funding round on 12/13/2023. Backers included Alexandria Venture Investments, Andreessen Horowitz and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
12/13/2023
Transaction Type
Venture Equity
Amount
$213,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
100 Talcott Avenue
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Undisclosed
Website
Email Address
Overview
Operator of a biotechnology company intended to offer programmable gene insertion technology. The company's technology helps to insert any genetic sequence of any size at any location in any genome to detect and destroy deoxyribonucleic acid from similar bacteriophages during subsequent infections, enabling patients to cure through cell and genome engineering.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Kakkar
Chief Operating Officer
Edward Freedman
Chief Scientific Officer
Jonathan Finn
Chief Technical Officer
Matt Barrows
Co-Founder
Omar Abudayyeh
Co-Founder
Jonathan Gootenberg
Browse more venture capital transactions:
Prev: 12/13/2023: Aesyra venture capital transaction
Next: 12/13/2023: Zero Networks venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs